Chlamydia vaccine passes safety trial
A first-of-its-kind experimental chlamydia vaccine trial has been found to be safe and able to provoke an immune response.
List view / Grid view
A first-of-its-kind experimental chlamydia vaccine trial has been found to be safe and able to provoke an immune response.
The European Commission has approved the drug for two indications: chronic lymphocytic leukaemia and Waldenström's macroglobulinemia.
In order keep up-to-date records and protect public health the FDA has announced it intends to deactivate out-of-date drug listings.
An open letter has underscored the challenges of return failure in the US drug supply chain, especially after the introduction of the Drug Supply Chain Security Act in November.
Lidocaine topical cream and liquid gel products are being recalled as the lidocaine amount is higher than the label states.
An Ebola clinical trial has been stopped early as Regeneron's REGN-EB3 therapy shows superiority to ZMapp in preventing Ebola deaths.
The US District Court has decided in favour of Amgen’s Enbrel, ruling over Sandoz’s Erelzi in a patent conflict.
The US District Court has ruled in favour of Eli Lilly in the Alimta patent lawsuit against Dr. Reddy's Laboratories and Hospira, Inc.
A treatment for Centronuclear Myopathies has received Orphan Drug Designation from the FDA and will begin Phase I/II trials.
A new systematic review has shown that the speed and quality of clinical trial reports are improved by professional medical writers.
The NICE and NHS have announced their draft recommendations for the prescribed use of cannabis-based treatments.
2019 has seen a marked increase of antibody biosimilar product approvals in the first half of the year, according to a report.
The global alopecia treatment market is projected to exhibit a CAGR of 4.9 percent from 2018–2026.
A new process developed by the University of Bath protects a TB antigen and a novel vaccine adjuvant from heat damage.
Pharma contract placement was found to increase by 250 percent compared to last year, according to figures from a recruitment firm.